Wound Relief Composition Stabilizing HIF-1alpha via PHD2 Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cutaneous wounds, particularly chronic wounds resulting from trauma, burns, surgery, or diabetes, are ineffective due to impaired responses to tissue hypoxia, leading to diminished healing and a need for alternative, side-effect-free therapeutic options.
Innovation Solution
A composition comprising von Hippel Lindau protein inhibitors such as meisoindigo, tanshinone IIA, and PHD2/EGLN1 protein inhibitors like glabridin, administered topically or systemically, to stabilize HIF-1α and promote wound healing by enhancing hypoxia response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional treatments are used for chronic wounds, then treatment simplicity is maintained, but wound healing effectiveness deteriorates due to impaired hypoxia response
Solution Approach 1:
The patent combines multiple natural product compounds (curcumin, resveratrol, quercetin, catechin, epigallocatechin gallate) into a single composition that works synergistically to inhibit PHD2 and stabilize HIF-1α, thereby improving wound healing effectiveness while maintaining treatment simplicity through a unified formulation
Solution Approach 2:
The treatment composition uses a composite of multiple natural product compounds with complementary mechanisms of action, where each compound contributes to PHD2 inhibition and HIF-1α stabilization, creating a synergistic effect that enhances overall therapeutic reliability
2Reliability
If PHD2 inhibition is enhanced to stabilize HIF-1α, then wound healing is improved, but the risk of adverse effects increases
Solution Approach 1:
The patent employs natural product compounds that are biodegradable and metabolized through normal physiological pathways, avoiding accumulation and long-term toxicity, thus reducing adverse effects while maintaining effective PHD2 inhibition for wound healing
Solution Approach 2:
The composition optimizes the concentrations and ratios of individual compounds (curcumin, resveratrol, quercetin, etc.) to achieve effective PHD2 inhibition at safe dosage levels, adjusting parameters to maximize therapeutic effect while minimizing adverse effects
3Reliability
If multiple compounds are combined in the composition, then therapeutic effectiveness is improved, but manufacturing complexity increases
Solution Approach 1:
Each compound in the composition (curcumin, resveratrol, quercetin, catechin, epigallocatechin gallate) serves multiple functions including PHD2 inhibition, HIF-1α stabilization, and anti-inflammatory activity, reducing the need for additional separate agents and simplifying manufacturing processes
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The composition effectively accelerates wound healing by stabilizing HIF-1α, improving angiogenesis and tissue regeneration, and reducing the formation of scars, with minimal adverse effects.
Implementation Method 1
a von Hippel Lindau protein inhibitor or an ARG-383 targeting component; and a PHD2/EGLN1 protein inhibitor or a HIS-313 targeting component
Implementation Method 2
to stabilize HIF-1α and promote wound healing by enhancing hypoxia response
Data Source
AI summary
Composition for administration to a subject comprising (a) an effective amount of a von Hippel Lindau protein inhibitor selected from meisoindigo, tanshinone IIA, 7-hydroxyflavone, dicumarol, flavone, tabersonine, danthron, equol, and pharmaceutically acceptable salts of each of the foregoing, and (b) an effective amount of a PHD2/EGLN1 protein inhibitor selected from glabridin, puerarin, wedelolactone, phlorizin and pharmaceutically acceptable salts of each the foregoing.